Kura Oncology to Participate in Bank of America Securities Healthcare Conference
May 08, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 08, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 03, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, May 03, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports First Quarter 2024 Financial Results
May 02, 2024 16:05 ET
|
Kura Oncology, Inc.
– Breakthrough Therapy Designation for ziftomenib in NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to complete enrollment by mid-2024 – – Positive...
Kura Oncology to Report First Quarter 2024 Financial Results
April 25, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 25, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Receives Breakthrough Therapy Designation for Ziftomenib in NPM1-Mutant AML
April 22, 2024 07:30 ET
|
Kura Oncology, Inc.
– Ziftomenib is the first investigational treatment to be granted Breakthrough Therapy Designation for NPM1-mutant AML – – Registration-directed trial of ziftomenib in NPM1-mutant AML on track to...
Kura Oncology to Participate in Stifel Targeted Oncology Forum
April 10, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 05, 2024 07:30 ET
|
Kura Oncology, Inc.
SAN DIEGO, April 05, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports First Patient Dosed in Trial of KO-2806 Plus Cabozantinib in Renal Cell Carcinoma
March 06, 2024 07:30 ET
|
Kura Oncology, Inc.
– Company anticipates dosing of KO-2806 in combination with adagrasib in KRASG12C-mutant NSCLC next quarter – – Dose escalation of KO-2806 as a monotherapy continues in parallel – SAN DIEGO, March ...
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
March 01, 2024 17:00 ET
|
Kura Oncology, Inc.
SAN DIEGO, March 01, 2024 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines...
Kura Oncology Reports Fourth Quarter and Full Year 2023 Financial Results
February 27, 2024 16:01 ET
|
Kura Oncology, Inc.
– Positive preliminary combination data from KOMET-007 trial of ziftomenib in NPM1-m and KMT2A-r AML, including effective mitigation of differentiation syndrome – – First patient dosed in KOMET-008...